May 08, 2018 - Cytosorbents Corp (NASDAQ:CTSO) has filed a financial statement reporting Sales Revenue Net of $4,924,651 USD. Previously, on November 09, 2017, Cytosorbents Corp reported Sales Revenue Net of $3,824,299 USD. This represents a change of 28.77% in Sales Revenue Net.

Period EndPeriodValue
2018-03-31 2018-Q1 4,924,651
2017-09-30 2017-Q3 3,824,299
2017-06-30 2017-Q2 3,566,226
2017-03-31 2017-Q1 3,113,518
2016-12-31 2016-Q4 3,083,615
2016-09-30 2016-Q3 2,411,708
2016-06-30 2016-Q2 2,222,338
2016-03-31 2016-Q1 1,810,182
2015-12-31 2015-Q4 1,760,978
2015-09-30 2015-Q3 1,343,625
2015-06-30 2015-Q2 963,939
2015-03-31 2015-Q1 723,074
2014-12-31 2014-Q4 873,660
2014-09-30 2014-Q3 1,162,347
2014-06-30 2014-Q2 1,024,655
2014-03-31 2014-Q1 1,062,172
2013-09-30 2013-Q3 880,692
2013-06-30 2013-Q2 291,483
2013-03-31 2013-Q1 371,330
2012-09-30 2012-Q3 605,346
2012-06-30 2012-Q2 83,042
2012-03-31 2012-Q1 50,226
2011-09-30 2011-Q3 0

Other Interesting Charts

Accrued Expenses And Other Current Liabilities - Advertising Expense - Allocated Share Based Compensation Expense - Deferred Tax Assets Tax Deferred Expense Reserves And Accruals - Finite Lived Intangible Assets Amortization Expense Next Twelve Months - Finite Lived Intangible Assets Amortization Expense Year Five - Finite Lived Intangible Assets Amortization Expense Year Four - Finite Lived Intangible Assets Amortization Expense Year Three - Finite Lived Intangible Assets Amortization Expense Year Two - Foreign Income Tax Expense Benefit Continuing Operations - Income Tax Expense Benefit - Increase Decrease In Deferred Revenue - Increase Decrease In Prepaid Deferred Expense And Other Assets - Interest Income Expense Nonoperating Net - Lease And Rental Expense - Nonoperating Income Expense - Operating Expenses - Other Sales Revenue Net - Prepaid Expense And Other Assets Current - Research And Development Expense - Revenue From Grants - Sales Revenue Goods Net - Sales Revenue Net - Selling General And Administrative Expense - State And Local Income Tax Expense Benefit Continuing Operations -

Related News Stories

Cytosorbents Stock Could Score Big With Its Blood-Filtering Technology

2018-08-30 investorplace
Cytosorbents (NASDAQ:CTSO) is something of a hit in Europe but is virtually unknown in the U.S. (1-0)

Revisiting Cytosorbents

2018-08-12 seekingalpha
The stock of this name has almost tripled in the past year as investors have bid up this 'razor & razor blade' story. (1-0)

Cytosorbents' (CTSO) CEO Phillip Chan on Q2 2018 Results - Earnings Call Transcript

2018-08-04 seekingalpha
Good afternoon, and welcome to the Cytosorbents Second Quarter 2018 Financial and Operating Results Conference Call. [Operator Instructions] Please be advised that the call will be recorded at the company’s request. (1-2)

Cytosorbents' (CTSO) CEO Phillip Chan on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Good afternoon and welcome to the Cytosorbents' First Quarter 2018 financial and operating results conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded at the Company's request.

CUSIP: 23283X206